Mobile

A phase III, open, multicentre, extension study to assess the immune response following administration of an additional dose of GSK Biologicals’ 10-valent conjugate pneumococcal vaccine or Prevenar™ a...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-007605-37

A phase III, open, multicentre, extension study to assess the immune response following administration of an additional dose of GSK Biologicals’ 10-valent conjugate pneumococcal vaccine or Prevenar™ at approximately 4 years of age in children previously vaccinated with three primary doses of a pneumococcal conjugate vaccine in study 10PN-PD-DIT-003 (105554) and a booster dose of 23-valent pneumococcal plain polysaccharide vaccine in study 10PN-PD-DIT-008 BST: 003 (106623)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

•To assess the immune response following administration of an additional dose of GSK Biologicals’ 10-valent conjugate pneumococcal vaccine (10Pn-PD-DiT) at approximately 4 years of age in children previously vaccinated with 3 doses of 10Pn-PD-DiT vaccine followed by a single dose of 23vPS vaccine.

Critère d'inclusion

  • A single dose of either 10Pn-PD-DiT or Prevenar vaccine to healthy children previously primed with 3 primary doses of 10Pn-PD-DiT or Prevenar vaccine in study 10PN-PD-DIT-003 (105554) and a booster dose of Pneumovax 23 (23vPS) vaccine in study 10PN-PD-DIT-008 BST: 003 (106623)

Liens